Glucose metabolism and cancer

Current Opinion in Cell Biology

Volumn 18, Issue 6, 2006, Pages 598-608

  Shaw, Reuben J ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIINFECTIVE AGENT; BIGUANIDE; CYTOTOXIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1; IMATINIB; METFORMIN; RAPAMYCIN DERIVATIVE; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

CANCER; CANCER INHIBITION; CLINICAL TRIAL; DIABETES MELLITUS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; MITOCHONDRION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; ENERGY METABOLISM; GLUCOSE; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MULTIENZYME COMPLEXES; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES;

EID: 33750619348     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceb.2006.10.005     Document Type: Review

References (87)

1. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314
2. Garber K. Energy deregulation: licensing tumors to grow. Science 312 (2006) 1158-1159
3. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2 (2002) 683-693
4. Kahn B.B., Alquier T., Carling D., and Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1 (2005) 15-25
5. Hardie D.G., Hawley S.A., and Scott J.W. AMP-activated protein kinase - development of the energy sensor concept. J Physiol 574 (2006) 7-15
6. Alessi D.R., Sakamoto K., and Bayascas J.R. Lkb1-dependent signaling pathways. Annu Rev Biochem 75 (2006) 137-163
7. Hearle N., Schumacher V., Menko F.H., Olschwang S., Boardman L.A., Gille J.J., Keller J.J., Westerman A.M., Scott R.J., Lim W., et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 12 (2006) 3209-3215
8. Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B., Engles J.M., Westra W.H., Herman J.G., and Sidransky D. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62 (2002) 3659-3662
9. Carretero J., Medina P.P., Pio R., Montuenga L.M., and Sanchez-Cespedes M. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene 23 (2004) 4037-4040
10. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., Alessi D.R., and Hardie D.G. Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2 (2003) 28
11. Shaw R.J., Kosmatka M., Bardeesy N., Hurley R.L., Witters L.A., DePinho R.A., and Cantley L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101 (2004) 3329-3335
12. Sakamoto K., McCarthy A., Smith D., Green K.A., Grahame Hardie D., Ashworth A., and Alessi D.R. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J 24 (2005) 1810-1820. The first LKB1 tissue-specific deletion is reported and results in near complete loss of AMPK activation by contraction in skeletal muscle. It is genetically demonstrated in muscle that loss of LKB1 is required for glucose transport and restoration of ATP levels following contraction.
13. Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., Depinho R.A., Montminy M., and Cantley L.C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 (2005) 1642-1646. Deletion of LKB1 in liver of adult mice results in near complete loss of AMPK activation, indicating that LKB1 is the major upstream kinase of AMPK in these metabolic tissues. Mice lacking hepatic LKB1 display profound increases in gluconeogenesis, due in part to hyperactivation of the CREB coactivator TORC2. Mice lacking hepatic LKB1 are unable to lower glucose levels following metformin treatment, unlike their wild-type littermates.
14. 2+-dependent manner.
15. Hurley R.L., Anderson K.A., Franzone J.M., Kemp B.E., Means A.R., and Witters L.A. The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 280 (2005) 29060-29066
16. Woods A., Dickerson K., Heath R., Hong S.P., Momcilovic M., Johnstone S.R., Carlson M., and Carling D. C(Ca2+)/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2 (2005) 21-33
17. •].
18. 2+-dependent manner.
19. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003) 577-590
20. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
21. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
22. Bader A.G., Kang S., Zhao L., and Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5 (2005) 921-929
23. +/- mice that mimic the human PJS tumors show elevated mTOR signaling compared to the surrounding epithelium.
24. •].
25. Hahn-Windgassen A., Nogueira V., Chen C.C., Skeen J.E., Sonenberg N., and Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280 (2005) 32081-32089
26. Inoki K., Ouyang H., Zhu T., Lindvall C., Wang Y., Zhang X., Yang Q., Bennett C., Harada Y., Stankunas K., et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126 (2006) 955-968. Wnt signaling is known to activate mTOR signaling via inhibition of GSK-3. AMPK phosphorylation of TSC2 serves a priming event for GSK-3 phosphorylation of TSC2.
27. Liu L., Cash T.P., Jones R.G., Keith B., Thompson C.B., and Simon M.C. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 21 (2006) 521-531
28. •] and LKB1-deficient liver [13]. Suggests that mTOR activation may be a relevant consequence of LKB1 loss in lung tumorigenesis.
29. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., and Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102 (2005) 8573-8578
30. Imamura K., Ogura T., Kishimoto A., Kaminishi M., and Esumi H. Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 287 (2001) 562-567
31. 1 cell cycle arrest that is dependent on AMPK and p53 tumor suppressor. Constitutively active AMPK induces growth arrest or senescence dependent on p53 activation. AMPK activation induces phosphorylation of p53 on serine 15, the previously described ATM/ATR site.
32. Igata M., Motoshima H., Tsuruzoe K., Kojima K., Matsumura T., Kondo T., Taguchi T., Nakamaru K., Yano M., Kukidome D., et al. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 97 (2005) 837-844
33. Mandal S., Guptan P., Owusu-Ansah E., and Banerjee U. Mitochondrial regulation of cell cycle progression during development as revealed by the tenured mutation in Drosophila. Dev Cell 9 (2005) 843-854. This paper reports the isolation of a Drosophila mutant, tenured, that exhibits reduced cell cycle progression associated with reduced cyclin E levels. Tenured encodes a mitochondrial electron transport chain subunit that, when inhibited, activates fly AMPK and subsequently fly p53 to regulate cyclin E levels.
34. Bettencourt-Dias M., Giet R., Sinka R., Mazumdar A., Lock W.G., Balloux F., Zafiropoulos P.J., Yamaguchi S., Winter S., Carthew R.W., et al. Genome-wide survey of protein kinases required for cell cycle progression. Nature 432 (2004) 980-987. An RNAi screen for kinases regulating various stages of cell cycle in Drosophila S2 cells. Amongst the many interesting findings is that AMPK α and γ subunits cause defects in S phase progression.
35. •]. For initial study, authors focus solely on regulators of mitotic progression and proliferation. Loss of AMPK α and γ subunits causes some of the largest observed increases in mitotic index.
36. Bardeesy N., Sinha M., Hezel A.F., Signoretti S., Hathaway N.A., Sharpless N.E., Loda M., Carrasco D.R., and DePinho R.A. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419 (2002) 162-167
37. Laderoute K.R., Amin K., Calaoagan J.M., Knapp M., Le T., Orduna J., Foretz M., and Viollet B. 5′-AMP-activated protein kinase (AMPK) Is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 26 (2006) 5336-5347. The authors analyze the relationship between HIF-1α and AMPK following hypoxia in genetically deficient mouse embryonic fibroblasts (MEFs). Increases in HIF levels and AMPK activation following hypoxia are independent of one another. Activation of AMPK is enriched in hypoxic necrotic regions of tumor xenografts. Ras-transformed AMPK-deficient MEFs are severely limited in their ability to form tumors compared to wild-type controls.
38. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
39. Semenza G.L., Roth P.H., Fang H.M., and Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269 (1994) 23757-23763
40. Iyer N.V., Kotch L.E., Agani F., Leung S.W., Laughner E., Wenger R.H., Gassmann M., Gearhart J.D., Lawler A.M., Yu A.Y., et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12 (1998) 149-162
41. Ryan H.E., Lo J., and Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17 (1998) 3005-3015
42. Greijer A.E., van der Groep P., Kemming D., Shvarts A., Semenza G.L., Meijer G.A., van de Wiel M.A., Belien J.A., van Diest P.J., and van der Wall E. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206 (2005) 291-304
43. Kim W.Y., and Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 22 (2004) 4991-5004
44. Brugarolas J., and Kaelin Jr. W.G. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6 (2004) 7-10
45. Dekanty A., Lavista-Llanos S., Irisarri M., Oldham S., and Wappner P. The insulin-PI3K/TOR pathway induces a HIF-dependent transcriptional response in Drosophila by promoting nuclear localization of HIF-α/Sima. J Cell Sci 118 (2005) 5431-5441. A thorough study demonstrating that endogenous insulin/PI3K/Akt/mTOR signaling regulates the Drosophila Hif-1α ortholog Sima, stabilizing its levels, promoting its nuclear accumulation and driving HRE-dependent transcription even in normoxic conditions.
46. Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., and Kaelin Jr. W.G. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4 (2003) 147-158
47. Blancher C., Moore J.W., Robertson N., and Harris A.L. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 61 (2001) 7349-7355
48. Li Y.M., Zhou B.P., Deng J., Pan Y., Hay N., and Hung M.C. A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res 65 (2005) 3257-3263
49. •] cells. In both species, expression of these genes is induced by Hif-1α, suggesting a negative feedback onto mTOR signaling from HIF-1 α.
50. •].
51. Pozuelo Rubio M., Peggie M., Wong B.H., Morrice N., and MacKintosh C. 14-3-3s regulate fructose-2,6-bisphosphate levels by binding to PKB-phosphorylated cardiac fructose-2,6-bisphosphate kinase/phosphatase. EMBO J 22 (2003) 3514-3523
52. Majewski N., Nogueira V., Bhaskar P., Coy P.E., Skeen J.E., Gottlob K., Chandel N.S., Thompson C.B., Robey R.B., and Hay N. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16 (2004) 819-830
53. Marsin A.S., Bertrand L., Rider M.H., Deprez J., Beauloye C., Vincent M.F., Van den Berghe G., Carling D., and Hue L. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 10 (2000) 1247-1255
54. Almeida A., Moncada S., and Bolanos J.P. Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat Cell Biol 6 (2004) 45-51
55. •], the authors demonstrate that pyruvate dehydrogenase kinase is a HIF-1 target gene and is responsible for actively inhibiting oxidative phosphorylation when HIF-1 mediated glycolysis is turned off. These findings finalize the mechanistic hypothesis of how simply activating HIF-1 could mediate the Warburg effect - increasing glycolysis and turning down OXPHOS.
56. •].
57. Bui T., and Thompson C.B. Cancer's sweet tooth. Cancer Cell 9 (2006) 419-420
58. Ullah M.S., Davies A.J., and Halestrap A.P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 281 (2006) 9030-9037
59. Fantin V.R., St-Pierre J., and Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9 (2006) 425-434. To investigate the requirement for lactate production in neu-transformed tumor cells, RNAi is used to inhibit lactate dehydrogenase expression. This inhibition leads to a direct increase in oxidative phosphorylation and a change in mitochondrial potential, which is accompanied by sensitivity to growth under hypoxic conditions and suppression of tumorigenicity.
60. •].
61. •] report the identification of two new p53 target genes: an inhibitor of glycolysis (TIGAR) and a stimulator of oxidative phosphorylation (SCO2). Given that loss of p53 occurs in a majority of human cancers, regulation of glucose metabolism by p53 may be a critical underappreciated aspect of its tumor suppressor function. Further work is needed.
62. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., and Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 14 (2000) 34-44
63. Kondoh H., Lleonart M.E., Gil J., Wang J., Degan P., Peters G., Martinez D., Carnero A., and Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res 65 (2005) 177-185
64. Eng C., Kiuru M., Fernandez M.J., and Aaltonen L.A. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 3 (2003) 193-202
65. Gottlieb E., and Tomlinson I.P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 5 (2005) 857-866
66. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., Pan Y., Simon M.C., Thompson C.B., and Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7 (2005) 77-85
67. Pollard P.J., Briere J.J., Alam N.A., Barwell J., Barclay E., Wortham N.C., Hunt T., Mitchell M., Olpin S., Moat S.J., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14 (2005) 2231-2239
68. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., Zhuang H., Cinalli R.M., Alavi A., Rudin C.M., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64 (2004) 3892-3899. One of the first studies to functionally demonstrate that glucose uptake and glycolysis occur downstream of Akt activation. Also demonstrates that this predisposes these cells to death by glucose deprivation.
69. Buzzai M., Bauer D.E., Jones R.G., Deberardinis R.J., Hatzivassiliou G., Elstrom R.L., and Thompson C.B. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation. Oncogene 24 (2005) 4165-4173
70. Ramanathan A., Wang C., and Schreiber S.L. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 102 (2005) 5992-5997. A systematic study examining metabolite production, oxygen consumption and sensitivity to glycolytic or OXPHOS inhibitors in a panel of cells progressively transformed by different oncogenes. Similar studies should be performed with more human oncogenes and/or tumor suppressor shRNAs in cell types where they are known to be critically mutated.
71. Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW, Chesney J: Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 2006, in press.
72. Hatzivassiliou G., Zhao F., Bauer D.E., Andreadis C., Shaw A.N., Dhanak D., Hingorani S.R., Tuveson D.A., and Thompson C.B. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8 (2005) 311-321
73. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., and Johnson R.S. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 60 (2000) 4010-4015
74. Kondo K., Klco J., Nakamura E., Lechpammer M., and Kaelin Jr. W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (2002) 237-246
75. Rankin E.B., Higgins D.F., Walisser J.A., Johnson R.S., Bradfield C.A., and Haase V.H. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol 25 (2005) 3163-3172
76. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 (2004) 594-601. Transgenic mice expressing constitutive Akt in the ventral prostate epithelium develop hyperplasia dependent on mTOR activation. Expression profiling reveals that of all transcripts, HIF-1-dependent glycolytic enzyme expression correlated best with tumor initiation and regression by rapamycin.
77. Bedogni B., Welford S.M., Cassarino D.S., Nickoloff B.J., Giaccia A.J., and Powell M.B. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 8 (2005) 443-454
78. Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., Czernin J., and Sawyers C.L. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 (2006) 122-127. Tumors lacking VHL and thus exhibiting constitutive activation of Hif-1α are inhibited by rapamycin, despite the fact that HIF-1 hyperaction is not initially due to increased mTOR signaling.
79. Granville C.A., Memmott R.M., Gills J.J., and Dennis P.A. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 12 (2006) 679-689
80. Serkova N., and Boros L.G. Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. Am J Pharmacogenomics 5 (2005) 293-302
81. Luo Z., Saha A.K., Xiang X., and Ruderman N.B. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26 (2005) 69-76
82. Motoshima H., Goldstein B.J., Igata M., and Araki E. AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574 (2006) 63-71
83. He G., Sung Y.M., Digiovanni J., and Fischer S.M. Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity. Cancer Res 66 (2006) 1873-1878
84. Anisimov V.N., Berstein L.M., Egormin P.A., Piskunova T.S., Popovich I.G., Zabezhinski M.A., Kovalenko I.G., Poroshina T.E., Semenchenko A.V., Provinciali M., et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40 (2005) 685-693
85. Schneider M.B., Matsuzaki H., Haorah J., Ulrich A., Standop J., Ding X.Z., Adrian T.E., and Pour P.M. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120 (2001) 1263-1270
86. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., and Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 330 (2005) 1304-1305. Pilot study examining cancer risk in type 2 diabetics taking metformin.
87. Bowker S.L., Majumdar S.R., Veugelers P., and Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29 (2006) 254-258